U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV
This article was originally published in PharmAsia News
TOKYO - Eisai said Aug. 24 that it had obtained U.S. FDA approval for an oral capsule formulation of Aloxi (palonosetron) for preventing chemotherapy-induced nausea and voting, broadening the company's reach into the CINV market
You may also be interested in...
U.S. FDA has approved a new indication for Japan-based Eisai's Aloxi (palonosetron hydrochloride) for post-operative nausea and vomiting in the first 24 hours after surgery. The drug maker announced approval of the expanded indication March 3 for the drug it obtained through the acquisition of MGI Pharma earlier this year (PharmAsia News, Jan. 24, 2008).
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).